Tesamorelin

Overview

Tesamorelin (development code TH9507; brand names Egrifta, Egrifta SV, and Egrifta WR) is a stabilized synthetic analog of human growth hormone-releasing hormone (GHRH). Unlike most peptides documented on this site, tesamorelin is an FDA-approved prescription medication. It was approved by the U.S. Food and Drug Administration on November 10, 2010, for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, a condition in which antiretroviral therapy is associated with accumulation of visceral (intra-abdominal) adipose tissue.

Tesamorelin works by stimulating the body's own pituitary release of growth hormone (GH), rather than supplying GH directly. In this respect it belongs to the same broad pharmacological family as other growth hormone secretagogues such as CJC-1295 (also a GHRH analog) and the ghrelin-receptor agonist Ipamorelin, though tesamorelin is distinguished by its formal regulatory approval and its specific HIV-lipodystrophy indication.

Chemistry and structure

Tesamorelin is a 44-amino-acid peptide based on the sequence of human GHRH(1-44). Native GHRH is rapidly degraded in plasma (notably by dipeptidyl peptidase-4 at the N-terminus), giving it a very short biological life. To stabilize the molecule, a trans-3-hexenoic acid (hexenoyl) moiety is attached to the N-terminal tyrosine residue. This modification slows enzymatic breakdown while preserving the peptide's ability to bind and activate the GHRH receptor.

Despite the very short plasma half-life, once-daily subcutaneous dosing produces a pulse of GH secretion that is sufficient to drive the downstream metabolic effects observed in clinical trials.

Mechanism of action

Tesamorelin is a growth hormone-releasing factor (GRF / GHRH) analog. It binds to the GHRH receptor on the somatotroph cells of the anterior pituitary, stimulating the synthesis and pulsatile release of endogenous growth hormone. Circulating GH then acts on the liver and peripheral tissues to increase insulin-like growth factor 1 (IGF-1).

GH is both anabolic and lipolytic. The lipolytic action is thought to be particularly pronounced in visceral adipose tissue (VAT), which is metabolically active and GH-responsive. By restoring a more physiological, pulsatile pattern of GH secretion through the body's own regulatory axis, tesamorelin reduces visceral fat while largely sparing subcutaneous fat. Because it stimulates the native hypothalamic-pituitary axis (rather than supplying supraphysiologic exogenous GH), GH release remains subject to normal feedback regulation, including suppression by somatostatin and IGF-1.

Approved use and clinical evidence

The approved indication is the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The approval rested principally on two large, randomized, double-blind, placebo-controlled phase 3 trials and their extension data.

Falutz et al., NEJM 2007 (pivotal trial). In this multicenter randomized trial of HIV-infected patients with abdominal fat accumulation, participants received tesamorelin 2 mg subcutaneously daily or placebo for 26 weeks. Tesamorelin produced a roughly 15% reduction in visceral adipose tissue versus a small increase with placebo (statistically significant), along with improvements in triglycerides and other lipid measures, and an increase in IGF-1. The reduction in fat was relatively selective for the visceral compartment.

Falutz et al., JCEM 2010 (pooled analysis). This pooled analysis combined two phase 3 trials (more than 800 patients) with safety-extension data. It confirmed significant VAT reduction with tesamorelin 2 mg daily versus placebo over 26 weeks, with continued benefit during extended treatment in those who remained on therapy. The analysis also illustrated that the visceral-fat benefit reverses after discontinuation, indicating that the effect depends on continued treatment.

Stanley et al., Lancet HIV 2019 (investigational NAFLD trial). In a separate randomized, double-blind trial in people with HIV and non-alcoholic fatty liver disease (NAFLD), tesamorelin 2 mg daily for 12 months reduced hepatic fat fraction and was associated with less fibrosis progression compared with placebo. This is an investigational (non-approved) use that has informed ongoing research interest in tesamorelin and liver fat.

The approved-use evidence (HIV-associated visceral lipodystrophy) should be kept separate from investigational or off-label contexts (e.g., NAFLD, general body-composition or "anti-aging" use), where the regulatory evidence base is absent or incomplete.

Safety, adverse effects and contraindications

Because tesamorelin raises GH and IGF-1, its safety profile centers on the known consequences of GH-axis stimulation. The following reflect the U.S. prescribing information.

Contraindications (per FDA label):

• Disruption of the hypothalamic-pituitary axis (e.g., from hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation, or head trauma).
• Active malignancy. Any preexisting malignancy should be inactive and its treatment complete before starting. The concern is that GH/IGF-1 may promote tumor growth.
• Pregnancy. Discontinue if a patient becomes pregnant. In animal studies, tesamorelin was associated with fetal harm (hydrocephaly in offspring at multiples of the clinical dose).
• Known hypersensitivity to tesamorelin or mannitol (an excipient).

Warnings and precautions:

• IGF-1 elevation: IGF-1 levels should be monitored during therapy; discontinuation should be considered for persistent, marked elevations (e.g., above approximately +2 to +3 standard deviation score), given theoretical neoplastic risk.
• Glucose intolerance / diabetes: Glucose status should be evaluated before and during treatment; new or worsening glucose intolerance and diabetes have been reported (diabetes was more frequent on tesamorelin than placebo).
• Fluid retention: May cause edema, arthralgia, and carpal tunnel syndrome.
• Injection-site reactions: More common than with placebo (erythema, pruritus, pain, irritation).
• Hypersensitivity reactions: Patients should seek care for signs of a systemic allergic reaction.
• Acute critical illness: GH-axis stimulation has not been studied in this setting and warrants caution by analogy to GH therapy.

Common adverse reactions (>5% and more frequent than placebo) reported in trials include arthralgia, injection-site erythema and pruritus, pain in an extremity, peripheral edema, and myalgia.

A key practical point is that the visceral-fat benefit is not durable after stopping the drug: VAT tends to re-accumulate when tesamorelin is discontinued, so the approved use is framed as ongoing therapy with continued monitoring.

Regulatory status (FDA / EMA)

United States (FDA — approved):

• November 10, 2010: Original approval of Egrifta for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.
• 2019: Approval of a reformulated, more stable version, Egrifta SV, for the same indication.
• 2025: Approval of Egrifta WR (the "F8" formulation), again for excess visceral abdominal fat in adults with HIV-associated lipodystrophy.

Tesamorelin is the only GHRH analog with active FDA approval in the United States. It is a prescription-only drug; it is not approved for weight loss, bodybuilding, athletic performance, or "anti-aging."

European Union (EMA — not approved; application withdrawn):

• A centralized EU marketing authorization application for Egrifta (tesamorelin) 2 mg was submitted by Ferrer Internacional, S.A. on 31 May 2011, seeking approval for excess visceral adipose tissue (VAT >130 cm²) in treatment-experienced HIV patients.
• On 21 June 2012, Ferrer voluntarily withdrew the application after the CHMP indicated that the data did not support a positive benefit-risk balance.
• The CHMP's concerns centered on sustained IGF-1 elevation (with theoretical cancer and diabetic-retinopathy risk), lack of long-term safety data for a treatment likely to be used chronically, absence of a cardiovascular outcome endpoint, questions about the clinical meaningfulness of the fat reduction, and applicability of the trial populations to European patients.

Off-label and unapproved-source use (caution)

Beyond its approved HIV-lipodystrophy indication, tesamorelin is sometimes discussed in the context of general visceral-fat reduction, liver fat / NAFLD (investigational, per Stanley et al. 2019), body composition, and "anti-aging" or wellness protocols, often alongside other secretagogues such as CJC-1295 or Ipamorelin. These uses fall outside the FDA-approved indication and, in most non-HIV populations, lack the controlled long-term outcome data needed to establish a favorable benefit-risk balance.

Key safety-relevant considerations that apply regardless of the source include the GH/IGF-1-related cautions above: potential for glucose intolerance, fluid retention, the contraindications in active malignancy and pregnancy, and the need for IGF-1 monitoring.

How it compares

Tesamorelin is the only FDA-approved peptide among the growth-hormone agents documented here, but its approval is narrow (reduction of excess visceral fat in HIV-associated lipodystrophy):

• Sermorelin is a related GHRH analog that was previously FDA-approved and is now discontinued/compounded.
• CJC-1295, Ipamorelin, GHRP-2 and GHRP-6 are research chemicals that are not approved for any use.

So while several peptides act on the GH/IGF-1 axis, only Tesamorelin currently carries a regulatory approval, and only for its specific indication. The others should not be assumed to share its evidence or safety standing. See the Muscle & growth hormone overview.

Common misconceptions

---

This article is provided for educational purposes only and is not medical advice. Tesamorelin (Egrifta) is a prescription medication that should be used only under the supervision of a qualified healthcare professional, who can assess contraindications and provide the laboratory monitoring required for safe use. Nothing here should be interpreted as encouragement to obtain or use tesamorelin outside of an approved, supervised clinical context.

Community claims & recent evidence

The points below address claims circulating in the peptide community — including popular video "masterclasses" — checked against primary sources. A knowledgeable creator is not peer review; every statement was treated as a claim to verify, not a fact.

Verified additions

• Tesamorelin augments the body's own pulsatile GH secretion rather than clamping GH high like exogenous growth hormone. In 13 healthy men, two weeks of tesamorelin increased basal and pulsatile overnight GH and raised IGF-1 while preserving insulin-stimulated glucose uptake [Human] (Stanley et al., J Clin Endocrinol Metab 2011). This supports the "stimulates your own axis, not GH replacement" framing.
• The visceral-fat effect is selective, not general fat loss. In the pivotal trial, tesamorelin 2 mg/day reduced visceral adipose tissue by ~15% while subcutaneous fat, limb fat and total body weight barely changed [Human] (Falutz et al., N Engl J Med 2007).
• A plausible mechanistic basis for that selectivity is that visceral (omental) adipocytes tend to express more GH receptor and be more GH-responsive than subcutaneous fat — though the depot difference is inconsistent and varies with adiposity [Human]/[In vitro] (reviewed in Lewitt, Biomark Insights 2017).
• The biological effect outlasts the peptide itself. Tesamorelin is cleared from plasma quickly — the FDA labels give a mean elimination half-life that is formulation-dependent: ~8 min for EGRIFTA SV, ~11 min for EGRIFTA WR, and ~26 min (healthy subjects) / ~38 min (HIV patients) for the original EGRIFTA (1 mg/vial) formulation — but it acts by triggering a GH→hepatic IGF-1 cascade; IGF-1 circulates bound to binding proteins and persists far longer, which is why the drug is labelled for once-daily dosing [Human].

Claims that don't hold up

• "A 2002 Rasmussen JCEM paper showed tesamorelin induces pulsatile GH." The pulsatility itself is real, but the citation is not: tesamorelin (TH9507) was not in clinical study under that name in 2002, and no such paper resolves. The actual primary source is Stanley et al., J Clin Endocrinol Metab 2011. Misattributed citation.
• "A 2010 Sinha JCEM study showed tesamorelin targets visceral fat." The visceral-selectivity evidence comes from the Falutz trials (N Engl J Med 2007; J Clin Endocrinol Metab 2010), not a "Sinha 2010." Misattributed citation.
• "Stacking 5-amino-1MQ works by antagonising SIRT1 / it is an NAD⁺-salvage inhibitor (Nature Metabolism 2019)." The mechanism is backwards. 5-amino-1MQ inhibits NNMT, which raises intracellular NAD⁺ and activates SIRT1 [Animal] (Neelakantan et al., Biochem Pharmacol 2018) — the opposite of SIRT1 antagonism. That work is mouse-only; there is no human trial of 5-amino-1MQ and no trial of any tesamorelin + 5-amino-1MQ combination, and the cited "Nature Metabolism 2019" paper does not resolve.
• "GH-induced insulin resistance is a desired anabolic feature of the protocol." In supervised use this is a monitored risk, not a benefit: the FDA label lists new or worsening glucose intolerance and diabetes as a warning, and the cleanest human pulsatility study actually found insulin sensitivity preserved, not usefully impaired [Human] (Stanley et al., 2011). Reframing a labelled hazard as a feature is not supported.
• The elaborate sodium-cycling, potassium, DIM, berberine and MOTS-c "protocol" citations (e.g. "2008 Redmond," "2017 Zhang," "2011 Müller," "2015 Lou," "2019 Peterson") could not be resolved to real primary papers on tesamorelin, and describe dosing outside any approved indication. Treat as unsourced; this page gives no dosing protocol.

Frequently asked questions

Does tesamorelin cause water retention?

It can. Because tesamorelin raises growth hormone and IGF-1, fluid retention is an expected, label-listed effect — the FDA prescribing information reports peripheral edema, arthralgia (joint pain), and carpal tunnel syndrome, and these were more common on tesamorelin than placebo in the phase 3 trials [Human]. Reports of rapid multi-pound water gain "in 24–48 hours" circulate in the community but are anecdotal and not quantified in the controlled trials; treat specific figures as unsourced. Fluid-related symptoms are one of the reasons the approved use includes clinician oversight rather than self-management.

Does tesamorelin cause insomnia, and should it be injected in the morning or at night?

Prominent sleep disruption is not among the common labeled adverse reactions (which center on joint pain, injection-site reactions, edema and myalgia), so a strong insomnia signal is not established in the trial data [Human]. Popular claims that morning versus evening injection changes sleep, fat mobilization, or results are protocol theory, not tested findings — no controlled trial has compared injection timing for tesamorelin, and the approved product is simply labeled as a once-daily subcutaneous injection [Hypothesis]. This page gives no timing or dosing protocol; any such scheme should be regarded as unproven.

Does tesamorelin actually burn visceral fat, or is that a myth?

It genuinely reduces visceral fat — but not by "burning" fat directly. In the pivotal trial, tesamorelin 2 mg/day cut visceral adipose tissue by roughly 15% versus placebo while subcutaneous fat and body weight barely moved [Human] (Falutz et al., N Engl J Med 2007). The mechanism is indirect: it stimulates the body's own pulsatile GH release, and GH/IGF-1 drives lipolysis that is relatively selective for the GH-responsive visceral depot. So the "it does nothing" and "it melts all your fat" camps are both wrong — the effect is real, specific to visceral fat, and reverses once the drug is stopped.

What is the best time to take tesamorelin, and does taking it fasted matter?

There is no evidence-based "best time." The approved product is labeled as a once-daily subcutaneous injection, and no controlled trial has shown that taking it fasted, before your largest meal, or at a particular hour changes fat loss or safety outcomes [Hypothesis]. The elaborate meal-timing and fasting rules seen in online protocols are unsourced extrapolations from GH–insulin physiology, not trial results. This page is educational and deliberately gives no dosing or timing instructions.

Does tesamorelin's short half-life mean you need to inject it several times a day?

No. Tesamorelin clears from plasma quickly — the FDA labels give a mean elimination half-life of roughly 8 minutes (Egrifta SV) up to about 26–38 minutes for the original formulation [Human] — but it works by triggering a GH → hepatic IGF-1 cascade, and IGF-1 circulates bound to binding proteins and persists far longer. That is precisely why the drug is labeled for once-daily dosing. Splitting it into multiple daily injections chasing the short half-life is not supported by the approved use.

Do you need to take DIM or manage estrogen while using tesamorelin?

No such requirement exists in the evidence. DIM, aromatase-related "estrogen management," and the aquaporin-channel rationale offered for them are not part of tesamorelin's approved use and have no controlled data in this context [Hypothesis]. The monitoring that the approved indication actually calls for is IGF-1 and blood-glucose testing under a clinician — not add-on estrogen agents. Bundled "support stack" protocols should be treated as unsourced.